Beijing Science Sun Pharmaceutical Co., Ltd. (SHE:300485)
China · Delayed Price · Currency is CNY 11.07
+0.03 (0.27%)
Feb 4, 2026, 3:04 PM CST
SHE:300485 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 400.7 | 414.95 | 475.92 | 733.73 | 1,050 | 1,094 |
Other Revenue | 1.53 | 1.53 | 0.65 | 0.82 | 1.15 | 0.28 |
| 402.23 | 416.48 | 476.57 | 734.55 | 1,051 | 1,094 | |
Revenue Growth (YoY) | -0.84% | -12.61% | -35.12% | -30.10% | -3.97% | -8.12% |
Cost of Revenue | 139.31 | 143.23 | 140.94 | 171.61 | 182.12 | 178.28 |
Gross Profit | 262.91 | 273.26 | 335.63 | 562.94 | 868.68 | 915.95 |
Selling, General & Admin | 190.66 | 199.12 | 292.63 | 429.92 | 658.62 | 702.9 |
Research & Development | 54.4 | 46.22 | 77.73 | 100.63 | 103.84 | 71.67 |
Other Operating Expenses | 8.57 | 6.65 | 6.61 | 8.76 | 11.74 | 10.22 |
Operating Expenses | 253.72 | 250.81 | 375.38 | 538.7 | 773.27 | 792.36 |
Operating Income | 9.19 | 22.44 | -39.75 | 24.24 | 95.41 | 123.59 |
Interest Expense | - | - | - | - | - | -0.18 |
Interest & Investment Income | 20.33 | 1.71 | 60.91 | 87.19 | 144.34 | 39.79 |
Currency Exchange Gain (Loss) | 0 | 0 | 0 | -0 | -0 | - |
Other Non Operating Income (Expenses) | 0.44 | 0.25 | -0.05 | -0.33 | -0.26 | -0.2 |
EBT Excluding Unusual Items | 29.97 | 24.4 | 21.11 | 111.1 | 239.49 | 162.99 |
Gain (Loss) on Sale of Investments | 78.26 | -108.13 | 100.27 | 125.41 | 185.65 | 14.81 |
Gain (Loss) on Sale of Assets | 0.11 | - | 0 | 6.65 | 6.57 | 0.17 |
Asset Writedown | -11.37 | - | - | -0.04 | -0 | -0.23 |
Other Unusual Items | 0.1 | 0.1 | 0.74 | 11.43 | 7.2 | 1.54 |
Pretax Income | 97.13 | -83.57 | 122.16 | 254.62 | 439.02 | 179.29 |
Income Tax Expense | 23.25 | -6.69 | 25.76 | 51.97 | 43.89 | 28.01 |
Earnings From Continuing Operations | 73.88 | -76.87 | 96.41 | 202.65 | 395.13 | 151.28 |
Minority Interest in Earnings | 7.32 | 8.02 | 6.51 | 2.09 | 7.14 | 3.62 |
Net Income | 81.2 | -68.85 | 102.92 | 204.73 | 402.27 | 154.9 |
Net Income to Common | 81.2 | -68.85 | 102.92 | 204.73 | 402.27 | 154.9 |
Net Income Growth | - | - | -49.73% | -49.10% | 159.69% | 4.21% |
Shares Outstanding (Basic) | 477 | 492 | 490 | 476 | 479 | 484 |
Shares Outstanding (Diluted) | 477 | 492 | 490 | 476 | 479 | 484 |
Shares Change (YoY) | -4.35% | 0.35% | 2.93% | -0.58% | -1.07% | 0.96% |
EPS (Basic) | 0.17 | -0.14 | 0.21 | 0.43 | 0.84 | 0.32 |
EPS (Diluted) | 0.17 | -0.14 | 0.21 | 0.43 | 0.84 | 0.32 |
EPS Growth | - | - | -51.16% | -48.81% | 162.50% | 3.23% |
Free Cash Flow | -29.45 | 34.85 | -31.7 | 67.15 | 137.38 | 145.88 |
Free Cash Flow Per Share | -0.06 | 0.07 | -0.07 | 0.14 | 0.29 | 0.30 |
Dividend Per Share | - | - | 0.022 | 0.086 | 0.168 | 0.065 |
Dividend Growth | - | - | -74.42% | -48.81% | 158.46% | 4.84% |
Gross Margin | 65.36% | 65.61% | 70.43% | 76.64% | 82.67% | 83.71% |
Operating Margin | 2.29% | 5.39% | -8.34% | 3.30% | 9.08% | 11.29% |
Profit Margin | 20.19% | -16.53% | 21.60% | 27.87% | 38.28% | 14.16% |
Free Cash Flow Margin | -7.32% | 8.37% | -6.65% | 9.14% | 13.07% | 13.33% |
EBITDA | 54.86 | 69.27 | 8.64 | 71.64 | 151.09 | 160.54 |
EBITDA Margin | 13.64% | 16.63% | 1.81% | 9.75% | 14.38% | 14.67% |
D&A For EBITDA | 45.66 | 46.83 | 48.39 | 47.39 | 55.68 | 36.96 |
EBIT | 9.19 | 22.44 | -39.75 | 24.24 | 95.41 | 123.59 |
EBIT Margin | 2.29% | 5.39% | -8.34% | 3.30% | 9.08% | 11.29% |
Effective Tax Rate | 23.94% | - | 21.08% | 20.41% | 10.00% | 15.62% |
Revenue as Reported | 402.23 | 416.48 | 476.57 | 734.55 | 1,051 | 1,094 |
Advertising Expenses | - | 1.93 | 2.4 | 137.51 | 293.09 | 281.34 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.